Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

COSCIENS Biopharma Inc T.AEZS

COSCIENS Biopharma Inc., formerly Aeterna Zentaris Inc., is a specialty biopharmaceutical company engaged in the development and commercialization of a diverse portfolio of pharmaceutical and diagnostic products, including those focused on areas of unmet medical need. Its lead product, macimorelin (Macrilen; Ghryvelin), is an oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). The Company is also engaged in the development of therapeutic assets and proprietary extraction technology, which is applied to the production of active ingredients from renewable plant resources used in cosmeceutical products (i.e., oat beta glucan and avenanthramides, which are found in skincare product brands like Aveeno and Burt’s Bees formulations) and being developed as potential nutraceuticals and/or pharmaceuticals.


TSX:AEZS - Post by User

Comment by prophetoffactzon Jul 25, 2024 9:27am
86 Views
Post# 36147708

RE:Re: Oct 8

RE:Re: Oct 8Commissioning of the 50L facility happened on schedule by the end of Q1 2024 and entered the fine tuning phase with three production runs as of April. Additionally, they delighted with the announcement that the product(PGX-YBG) could be available by year-end pending Health Canada approval. The 100L facility is expected to be commissioned this quarter with industry leader Natex and is the decision point for mass industrialization. Now we see PGX is expected to be showcased on October 8 at a conference of engineers. Based on the general time to publishing PGX-YBG/Fibrosis could also be published in the leading scientific publication Biomaterials in the next 1-2 months. It's all coming together. With approval for the name change of the company the new company name and symbol is very near. While expected in Q3 top-line diagnostic data appears imminent. 

Ronald W. Miller, Chair of the Company:

“With the successful completion of this merger, we are now optimized to bring value-driving, transformational products to the market.”



Hopeforthebest wrote: Hey proph that they will finally announce to commissioning of the PGX 50 scale is finally completed, after all it has been almost 8 months after the promised completion date and in true gagnon fashion failure and delays and lies


<< Previous
Bullboard Posts
Next >>